Related Experiment Video
Updated: Jul 23, 2026
11:35
The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS
R A Rudick1, G Cutter, M Baier
1Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA. rudick@ccf.org
Neurology
|May 29, 2001
Summary
The Multiple Sclerosis Functional Composite (MSFC) effectively predicts long-term disability and brain atrophy in relapsing-remitting MS (RR-MS) patients, aiding prognosis and monitoring.
Area of Science:
- Neurology
- Clinical Trials
- Disease Progression
Background:
- The Multiple Sclerosis Functional Composite (MSFC) was recommended as a novel clinical outcome measure for MS trials.
- MSFC integrates tests of walking, dexterity, and cognition into a single score.
- Its predictive value for disease progression in relapsing-remitting MS (RR-MS) remained undetermined.
Purpose of the Study:
- To assess the predictive capability of MSFC scores for future disease progression in RR-MS patients.
- To validate MSFC as a reliable outcome measure for long-term MS monitoring.
Main Methods:
- A follow-up study analyzed RR-MS patients from a phase III interferon beta-1a trial.
- MSFC scores were derived from baseline and 2-year data.
- Patients underwent neurologic, MRI, and quality of life assessments after an average of 8.1 years.
Main Results:
- MSFC scores strongly predicted clinical and MRI outcomes at follow-up.
- Baseline and 2-year MSFC scores correlated with disability and brain atrophy.
- MSFC showed a stronger correlation with brain atrophy than the EDSS score.
Conclusions:
- MSFC scores reliably predict disability and brain atrophy in RR-MS patients 6-8 years later.
- MSFC can aid in prognosis, patient monitoring, and treatment effect assessment.
- This highlights MSFC's utility in clinical practice and research for MS.
